Treatment Considerations for ASCVD & LDL-C Management

AHA 2022 Conference Coverage
K

AHA 2022: Long-Term Efficacy and Safety of Inclisiran in Patients With High Cardiovascular Risk and Elevated Low-Density Lipoprotein Cholesterol (ORION-3)

By AHA 2022 Conference Coverage FEATURING Kausik Ray
By AHA 2022 Conference Coverage FEATURING Kausik Ray
10,786 views
November 30, 2022
Comments 7
Login to view comments. Click here to Login
17:04

Non-Statin Therapies for Elevated LDL-C: The Role of Inclisiran (and…

Canadian Collaborative Research Network

J. Genest

872 views
42:26

Familial Hypercholesterolemia: From Diagnosis to Treatment

Scripps Health

P. Duell

352 views
12:20

HID 2023 Insights: LDL-C - How Low Can We Go Safely?

Seth Martin

2.8K views
33:43

Update on Lipids: Current Options for Lowering LDL to Reduce CV Risk

Jefferson Health

A. Cohen

4.1K views
42:28

Treatment of Lipids in 2023: Where Are We Now and Where Are We Going?

Houston Methodist DeBakey Heart and Vascular Center

C. Ballantyne

4.2K views
23:35

ENDO 2022: Targeting PCSK9 for LDL-C Reduction

Connie Newman

1.8K views
39:44

Lipid Lowering Therapies: Where Did We Start, Where We Are Now and W…

The Texas Heart Institute

S. Virani

5.5K views
21:27

Lipids Update: Current Guidelines for Lipid Management

Scripps Health

S. R. Mehta

10.7K views
30:02

Lipid Management & Low Carb Diets

Metabolic Health Summit

B. Scher

3.8K views
41:22

Non-Statin Pharmacotherapies for Risk Reduction

Scripps Health

M. Wilkinson

3.4K views
27:51

Lipids Update: Overview of Current Guidelines for Lipid Management

Scripps Health

D. Cork

1.7K views